ProCE Banner Activity

Predicting Virologic Failure Risk With LA CAB + RPV: Perspectives From Spain

Clinical Thought

As this new option starts to become available in Spain, I take a look at how new data presented at HIV Glasgow 2022 will affect my clinical practice.

Released: November 21, 2022

Share

Faculty

José R. Arribas

José R. Arribas, MD

Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

José R. Arribas, MD

Professor of Medicine
Department of Medicine
Autónoma University School of Medicine
Head, Infectious Diseases Unit
Department of Internal Medicine
Hospital La Paz
Madrid, Spain

Dr José Arribas discusses new HIV Glasgow 2022 data on risk factors for virologic failure with long-acting CAB + RPV, from Clinical Care Options (CCO)